Skip to content
value.today

GeneCentric Diagnostics, Inc.

🇺🇸 Durham, North Carolina, USABiotechnologyFounded 2011
Total raised
$18 M
4 rounds on record
Latest round
$2 M
Jun 2025
First round on record
Jun 2013
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of GeneCentric Diagnostics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2025$2 MNo. 4$2 to $10 million

GeneCentric Diagnostics, Inc.: Raise no. 4, Jun 2025

Investors in this round

9 investors had bought by the notice of Jun 20, 2025: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $5 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael Milburn · Executive Officer, Director
  • Arnold Levine · Director
  • Charles Perou · Director
  • Clay Thorp · Director
  • Don Hardison · Director
  • Myla Lai-Goldman · Director
  • Prasanth Reddy · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”

Signed by Michael Milburn, PhD, Ceo. Source: SEC Form D, newest notice filed Jun 20, 2025. Read the notice at the SEC.

equitySEC
Sep 2021$5 MNo. 3$2 to $10 million

GeneCentric Diagnostics, Inc.: Raise no. 3, Sep 2021

Investors in this round

1 investor had bought by the notice of Oct 7, 2021: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $8 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael V. Milburn · Executive Officer, Director
  • Myla V. Lai-Goldman · Executive Officer, Director
  • Perou V. Charles · Executive Officer, Director
  • Arnold V. Levine · Director
  • Clay V. Thorp · Director
  • Ellen V. Lubman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael V. Milburn, President and CEO. Source: SEC Form D, newest notice filed Oct 7, 2021. Read the notice at the SEC.

equitySEC
Dec 2016$6 MNo. 2$2 to $10 million

GeneCentric Diagnostics, Inc.: Raise no. 2, Dec 2016

Investors in this round

4 investors had bought by the notice of Jan 5, 2017: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $9 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Neil Hayes · Executive Officer, Director
  • Myla Lai-Goldman · Executive Officer, Director
  • Arnold Neil Levine · Director
  • Charles Neil Perou · Director
  • Clay Neil Thorp · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”

Signed by Myla Lai-Goldman, President and CEO. Source: SEC Form D, newest notice filed Jan 5, 2017. Read the notice at the SEC.

equitySEC
Jun 2013$5 MNo. 1$2 to $10 million

GeneCentric Diagnostics, Inc.: Raise no. 1, Jun 2013

Investors in this round

4 investors had bought by the notice of Jul 11, 2014: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Neil Hayes · Executive Officer, Director
  • Myla Lai-Goldman · Executive Officer, Director
  • Arnold Neil Levine · Director
  • Charles Neil Perou · Director
  • Clay Neil Thorp · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”

Signed by Myla Lai-Goldman, President and CEO. Source: SEC Form D and 1 amendment, newest notice filed Jul 11, 2014. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • GeneCentric Diagnostics, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2025).

    SEC Form D · Jun 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2025

That is all the official record says: GeneCentric Diagnostics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of GeneCentric Diagnostics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 9 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by GeneCentric Diagnostics, Inc.
NameRoleNamed in
Michael MilburnExecutive officerJun 2025
Michael V. MilburnExecutive officerOct 2021
Myla V. Lai-GoldmanExecutive officerOct 2021
Perou V. CharlesExecutive officerOct 2021
David Neil HayesExecutive officerJan 2017
Myla Lai-GoldmanExecutive officerJan 2017
Arnold LevineDirectorJun 2025
Charles PerouDirectorJun 2025
Clay ThorpDirectorJun 2025
Don HardisonDirectorJun 2025
Michael MilburnDirectorJun 2025
Myla Lai-GoldmanDirectorJun 2025
Prasanth ReddyDirectorJun 2025
Arnold V. LevineDirectorOct 2021
Clay V. ThorpDirectorOct 2021
Ellen V. LubmanDirectorOct 2021
Michael V. MilburnDirectorOct 2021
Myla V. Lai-GoldmanDirectorOct 2021
Perou V. CharlesDirectorOct 2021
Arnold Neil LevineDirectorJan 2017
Charles Neil PerouDirectorJan 2017
Clay Neil ThorpDirectorJan 2017
David Neil HayesDirectorJan 2017